IDO1 and cancer: The complexity of the TRP-depletion versus metabolite generation remains a puzzle of cellular biochemistry with a key practical implication: IDO1 inhibitors have thus far been unsuccessful in cancer therapy, despite IDO1 being one of the most rational and tractable pathways to target (Long et al., 2019).